We use cookies for a better user experience. Read our Privacy Policy

I Agree

Anthelmintic Drugs Market

Anthelmintic Drugs Market (Drug Class: Benzimidazoles, Piperazine, and Others; Route of Administration: Oral and Injectable; Application: Human [Parenchymal Neurocysticercosis and Gastrointestinal Infections] and Animal; Target Pathogen: Ascaris Lumbricoides [Roundworm], Trichuris Trichiura [Whipworm], Enterobius Vermicularis [Pinworm], Ancylostoma Duodenale [Hookworm], and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Veterinary Pharmacies, and Veterinary Hospitals & Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

AI-driven Drug Discovery Aids Approval of Niclosamide for COVID-19 Treatment

The ongoing COVID-19 (coronavirus) outbreak has fueled an unprecedented demand for drugs that are capable of fighting off the novel infection. Hence, AI (Artificial Intelligence) firm Gero is gaining global recognition for specializing in the AI-driven drug discovery and validating promising potentials of anthelmintic drugs for the treatment of COVID-19. As such, niclosamide is found to be potentially effective for the treatment of coronavirus in patients and has been approved in the U.S., Italy, France, and few other countries where there is a high prevalence of active COVID-19 patients.

Due to the approval of niclosamide, companies in the anthelmintic drugs market are increasing their efficacy in AI-driven drug discovery methods to capitalize on revenue generation opportunities. Companies in the anthelmintic drugs market are taking efforts to conduct clinical trials in existing drugs that may be useful in coronavirus treatment.

anthelmintic drugs market infographic

To know the scope of our report Get a Sample on Anthelmintic Drugs Market 

Sponsored Collaborations Fuel Research in New Drug Candidates for Soil-transmitted Infections

An alarmingly right prevalence of parasitic worm infections in humans has forced companies in the anthelmintic drugs market to increase their R&D capabilities for new drug candidates. For instance, in December 2019, Bayer Animal Health — a global provider of innovative solutions for animal health, revealed that the company is increasing its research efforts to provide promising anthelmintic drug candidates for the EU-sponsored collaboration called Project HELP (Helminth Elimination Platform) meant for human treatment.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies in the anthelmintic drugs market are entering into strategic collaborations in order to find new treatments for ascaris lumbricoides (Roundworm) infection. This explains why the revenue for roundworm target pathogen is estimated to dictate the highest value in the anthelmintic drugs market, resulting in anticipated revenue generation of ~US$ 4 Bn by the end of 2030. The growing awareness about soil-transmitted infections and filarial infections in humans is bolstering innovations in anthelmintic drugs.

Biologically Active Substances of Medicinal Plants Hold Promising Potentials for Drug Discovery

Plant-based products are being highly publicized for the development of anthelmintic drugs that are capable of treating nematodes. Currently, intestinal parasitic nematodes are a serious issue in human as well as animals. As such, animals dominate a higher revenue share as compared to humans in the anthelmintic drugs market, where the market is slated to progress at a CAGR of ~5% during the forecast period. However, anthelmintic drug resistance in humans and animals is a challenge for pharmaceutical companies. Hence, companies are using medicinal plant ingredients for the discovery of new anthelmintic drugs.

Companies in the anthelmintic drugs market are increasing their research efforts to study the biologically active substances of medicinal plants that possess drug-like properties and hold promising potentials for the treatment of intestinal parasitic nematodes in human as well as animals. As such, medicinal plant-derived drugs, such as artemether, tiopropium and galantamine are generating revenue streams for pharmaceutical companies.

Combination Therapy Awaits Confirmed Clinical Trials to Deploy Widespread Adoption in Veterinary Clinics

Various preventive measures are being adopted to control parasites in donkeys. Since vaccines are not readily available and there is a need for the development of better vaccines, veterinary doctors are relying on anthelmintic drugs to protect the health of donkeys. As such, companies in the anthelmintic drugs market are tapping value-grab opportunities by increasing the availability of benzimidazoles macrocyclic lactones and tetrahydropyrimidines to improve the health of donkeys.

In order to effectively manage the issue of drug resistance in donkeys, companies in the anthelmintic drugs market are educating veterinarians to gain better knowledge of local parasite epidemiology and its correlation with anthelmintic drugs. The trend of combination therapy is surging, as veterinarians are using different combination of drugs to improve clinical numbers of donkeys. However, there is a need for confirmed clinical trials to support the validation of combination therapy. Since donkeys ingest third-stage larvae from grazing, there is a need for sound grazing management practices. The practice of FEC (Fecal Egg Count)-directed treatment is another alternative treatment, which is benefitting the health of donkeys.

anthelmintic drugs market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

With the approval of niclosamide in the U.S. and Italy, AI is predicted to play a crucial role in drug discovery methodologies for COVID-19 treatment. As such, anti-cancer effects of anthelmintics are being recognized by healthcare systems in Korea.

Medicinal plants hold promising potentials for innovations in anthelmintics. However, anthelmintic resistance is a recurring problem that needs to be addressed by pharmaceutical companies. Hence, companies should sponsor research-based communities that conduct aggressive research on the prevention of anthelmintic resistance. They should direct their investments in preserving the drug efficacy and increase research in anthelmintic resistance management and awareness about hygienic grazing methods to improve the health of animals.

Anthelmintic Drugs Market: Overview

  • According to Transparency Market Research’s latest report on the global anthelmintic drugs market for the historical period 2018–2019 and forecast period 2020–2030, increase in incidence of helminth infection across the globe, innovative drug launch for gastrointestinal nematodes, government initiatives, and rise in pet ownership and spending on companion animals are expected to drive the global market during the forecast period
  • According to the report, the anthelmintic drugs market was valued at ~US$ 2 Bn in 2019 and is anticipated to expand at a CAGR of ~5% from 2020 to 2030

Increase in Incidence of Helminth Infection Worldwide: Key Drivers

  • Rise in prevalence of helminth infections caused by roundworm, hookworm, whipworm, and others worms is anticipated to drive the need of anthelmintic drugs for the treatment of the same
  • Soil transmitted helminth infections are caused by various species of parasitic worms. According to the WHO, as of March 2020, nearly 1.5 billion humans were suffering from soil transmitted helminth infection across the globe. This number accounts for 24% of the global human population. Major species increasing the disease burden are ascaris lumbricoides (roundworms), trichuris trichiura (whipworms), necator americanus, and ancylostoma duodenale (hookworms).
  • According to the WHO data, in March 2020, distribution of soil-transmitted helminth infection was higher in sub-Saharan Africa, the Americas, China, and countries in Asia. Globally, 267 million preschool children and 568 million schoolchildren in the above areas are suffering from helminth infections.
  • Moreover, S. stercoralis are estimated to be affecting around 600 million people globally. Poor hygiene and sanitation are the other factors boosting incidence of soil-transmitted helminth infections across the globe.

Government Initiatives to Boost Market Growth

  • Initiatives and paradigm shift in focus of governments toward contributing in managing the helminth infections across the globe are anticipated to boost the market for anthelmintic drugs
  • For instance, the National Deworming Day is a major initiative by the Ministry of Health and Family Welfare, Government of India, to make the country worm-free. According to the WHO, 241 million children in the age group 1 to 14 years are at a higher risk of parasitic intestinal worms in India. Hence, the government is likely to develop guidelines for creating awareness and eradicate helminth infection.
  • Anthelmintic drugs are the primary controlling measure for eradicating worms in livestock. Annual cost of parasitic diseases is estimated to be US$ 1 Bn in Australia and US$ 7.11 Bn in Brazil. Hence, standard policies for treatment of worm infection in humans and livestock are of prime importance in every country.

Anthelmintic Drug Resistance to Hamper Market

  • Anthelmintic drugs are the most preferred and efficient treatment for fighting helminthiasis in animals and humans. However, multidrug-resistance is a major concern in livestock, especially in the two new classes such as aminoacetonitrile derivatives and paraherquamide derivatives.
  • Rise in multidrug-resistance would pressurize producers and animal health professionals to develop alternative methods of treatment. Thus, rise in drug resistance to most commonly prescribed anthelmintic drugs by parasitic helminths is likely to restrain the market during the forecast period. Helminthiasis has been reported to develop resistance to drugs such as Levamisole, morantel, Benzimidazole, Albendazole, Avermectin, and Ivermectinin the past few years.
  • Resistance to anthelmintic drugs is a major concern in sheep-producing countries in Europe. Multidrug & multispecies resistance is increasing at a rapid pace in South America. This is anticipated to restrain the global anthelmintic drugs market. According to a research, resistance against monepantel and derquantel has already been reported, which has increased the risk factor associated with anthelmintic resistance.

Anthelmintic Drugs Market: Competition Landscape

  • This report profiles major players in the global anthelmintic drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global anthelmintic drugs market is highly fragmented with the presence of a number of international as well as regional players
  • Leading players operating in the global anthelmintic drugs market include 
    • Novartis AG
    • Cipla Inc.
    • Sun Pharmaceutical Industries Ltd
    • Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.)
    • Zoetis, Inc.
    • GlaxoSmithKline plc
    • Bayer AG
    • Merck & Co., Inc. (Intervet Inc.)
    • Boehringer Ingelheim International GmbH

Anthelmintic Drugs Market: Key Developments

  • Key players in the global anthelmintic drugs market are engaged in regulatory approval, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global anthelmintic drugs market. A few expansion strategies adopted by players operating in the global anthelmintic drugs market are:
    • In February 2020, Zoetis received approval for Simparica Trio drug, a combination used as a prevention for heartworm disease, roundworms, ricks, hookworms, and fleas in dogs
    • In April 2019, Janssen Pharmaceuticals Inc. announced that WHO has prequalified the company's new product VERMOX (Mebendazole) CHEWABLE for intestinal worms. After the WHO prequalification, this product is likely to be available for the children in the age group of 1 year, especially in high burden countries.
    • In May 2018, Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. completed their merger to form a new company known as Amneal Pharmaceuticals, Inc. This merger is likely to boost the generic business making Amneal as a fifth-largest generic business in the U.S.
    • In September 2018, Cipla announced receiving final approval of the Abbreviated New Drug Application (ANDA) for Albendazole 200 mg tablet
  • The report on the global anthelmintic drugs market discussed individual strategies, followed by company profiles of manufacturers of anthelmintic drugs. The competition landscape section has been included in the report to provide readers with a dashboard view of key players operating in the global anthelmintic drugs market.

Anthelmintic Drugs Market – Segmentation

Drug Class

Benzimidazoles

Piperazine

Others

Route of Administration

Oral

Injectable

Application

Human

  • Parenchymal Neurocysticercosis
  • Gastrointestinal Infections

Animal

Target Pathogen

 

Ascaris Lumbricoides (Roundworm)

Trichuris Trichiura (Whipworm)

Enterobius Vermicularis (Pinworm)

Ancylostoma Duodenale (Hookworm)

Others

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Veterinary Pharmacies

Veterinary Hospitals & Clinics

 

Region

Europe

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of anthelmintic drugs market?

The global anthelmintic drugs market was worth US$ 2 Bn and is projected to reach a value of US$ 4 Bn by the end of 2030

What is the anticipated CAGR of the anthelmintic drugs market in the forecast period?

Anthelmintic drugs market is anticipated to grow at a CAGR of 5% during the forecast period

Which region is expected to project the highest market share in anthelmintic drugs market?

Asia Pacific accounted for a major share of the global anthelmintic drugs market

What are the key driving factors for the growth of anthelmintic drugs market?

Anthelmintic drugs market is driven by increase in incidence of helminth infection across the globe, innovative drug launch for gastrointestinal nematodes, government initiatives, and rise in pet ownership and spending on companion animals are expected to drive the global market

Who are the key players in the global anthelmintic drugs market?

Key players in the global anthelmintic drugs market include Novartis AG, Zoetis, Inc., Amneal Pharmaceuticals Inc., Cipla Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Sun Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Bayer AG, Merck & Co. Inc.(Intervet Inc.), and Boehringer Ingelheim International GmbH

    1. Preface

       1.1. Market  Definition and Scope

       1.2. Market  Segmentation

       1.3. Key Research Objectives

       1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Anthelmintic Drugs Market 

    4. Market  Overview

       4.1. Introduction

           4.1.1. Market  Definition

           4.1.2. Industry Evolution / Developments

       4.2. Overview

       4.3. Market  Dynamics

           4.3.1. Drivers

           4.3.2. Restraints

           4.3.3. Opportunities

       4.4. Global Anthelmintic Drugs Market Analysis and Forecast, 2018–2030

           4.4.1. Market  Revenue Projections (US$ Mn)

    5. Key Insights

       5.1. Epidemiology of Helminthic Infections

       5.2. Key Industry Events (Product Launch, Approval, Acquisition, Merger, Collaboration, etc.)

       5.3. Impact of COVID-19 on Anthelmintic Drugs Market

    6. Global Anthelmintic Drugs Market Analysis and Forecast, by Drug Class   

       6.1. Introduction & Definition

       6.2. Key Findings / Developments

       6.3. Anthelmintic Drugs Market Value Forecast, by Drug Class, 2018–2030

           6.3.1. Benzimidazoles

           6.3.2. Piperazine

           6.3.3. Others

       6.4. Market Attractiveness Analysis, by Drug Class 

    7.   Global Anthelmintic Drugs Market Analysis and Forecast, by Route of Administration

       7.1. Introduction & Definition

       7.2. Key Findings / Developments

       7.3. Anthelmintic Drugs Market Value Forecast, by Route of Administration, 2018–2030

           7.3.1. Oral

           7.3.2. Injectable

       7.4. Market  Attractiveness Analysis, by Route of Administration

    8. Global Anthelmintic Drugs Market Analysis and Forecast, by Application

       8.1. Introduction & Definition

       8.2. Key Findings / Developments

       8.3. Anthelmintic Drugs Market Value Forecast, by Application, 2018–2030

           8.3.1. Human 

               8.3.1.1. Parenchymal Neurocysticercosis

               8.3.1.2. Gastrointestinal Infections

           8.3.2. Animal

       8.4. Market  Attractiveness Analysis, by Application

    9. Global Anthelmintic Drugs Market Analysis and Forecast, by Target Pathogen

       9.1. Introduction & Definition

       9.2. Key Findings / Developments

       9.3. Anthelmintic Drugs Market Value Forecast, by Target Pathogen, 2018–2030

           9.3.1. Ascaris Lumbricoides (Roundworm)

           9.3.2.  Trichuris Trichiura (Whipworm 

           9.3.3. Enterobius Vermicularis (Pinworm)

           9.3.4. Ancylostoma Duodenale (Hookworm)

           9.3.5. Others

       9.4. Market  Attractiveness Analysis, by Target Pathogen

    10. Global Anthelmintic Drugs Market Analysis and Forecast, by Distribution Channel  

       10.1. Introduction & Definition

       10.2. Key Findings / Developments

       10.3. Anthelmintic Drugs Market Value Forecast, by Distribution Channel, 2018–2030

           10.3.1. Hospital Pharmacies

           10.3.2. Retail Pharmacies

           10.3.3. Online Pharmacies

           10.3.4. Veterinary Pharmacies

           10.3.5. Veterinary Hospitals & Clinics

       10.4. Market  Attractiveness Analysis, by Distribution Channel 

    11. Global Anthelmintic Drugs Market Analysis and Forecast, by Region 

       11.1. Key Findings

       11.2. Anthelmintic Drugs Market Value Forecast, by Region

           11.2.1. Europe 

           11.2.2. Europe 

           11.2.3. Asia Pacific

           11.2.4. Latin America 

           11.2.5. Middle East & Africa

       11.3. Market  Attractiveness Analysis, by Region

    12. North America   Anthelmintic Drugs Market Analysis and Forecast

       12.1.  Introduction

           12.1.1.  Key Findings

       12.2.  North America Anthelmintic Drugs Market Value Forecast, by Drug Class, 2018–2030

           12.2.1. Benzimidazoles

           12.2.2. Piperazine

           12.2.3. Others

       12.3. North America Anthelmintic Drugs Market Value Forecast, by Route of Administration, 2018–2030

           12.3.1. Oral

           12.3.2. Injectable

       12.4. North America Anthelmintic Drugs Market Value Forecast, by Application, 2018–2030

           12.4.1. Human 

               12.4.1.1. Parenchymal Neurocysticercosis

               12.4.1.2. Gastrointestinal Infections

           12.4.2. Animal

       12.5. North America Anthelmintic Drugs Market Value Forecast, by Target Pathogen, 2018–2030

           12.5.1. Ascaris Lumbricoides (Roundworm)

           12.5.2.  Trichuris Trichiura (Whipworm 

           12.5.3. Enterobius Vermicularis (Pinworm)

           12.5.4. Ancylostoma Duodenale (Hookworm)

           12.5.5. Others

       12.6. North America Anthelmintic Drugs Market Value Forecast, by Distribution Channel, 2018–2030

           12.6.1. Hospital Pharmacies

           12.6.2. Retail Pharmacies

           12.6.3. Online Pharmacies

           12.6.4. Veterinary Pharmacies

           12.6.5. Veterinary Hospitals & Clinics

       12.7. North America Anthelmintic Drugs Market Value Forecast, by Country, 2018–2030

           12.7.1. U.S.

           12.7.2. Canada

       12.8. North America Anthelmintic Drugs Market Attractiveness Analysis

           12.8.1. By Drug Class   

           12.8.2. By Route of Administration

           12.8.3. By Application   

           12.8.4. By Target Pathogen

           12.8.5. By Distribution Channel  

           12.8.6. By Country

    13. Europe  Anthelmintic Drugs Market Analysis and Forecast

       13.1.  Introduction

           13.1.1.  Key Findings

       13.2.  Europe Anthelmintic Drugs Market Value Forecast, by Drug Class, 2018–2030

           13.2.1. Benzimidazoles

           13.2.2. Piperazine

           13.2.3. Others

       13.3. Europe Anthelmintic Drugs Market Value Forecast, by Route of Administration, 2018–2030

           13.3.1. Oral

           13.3.2. Injectable

       13.4. Europe Anthelmintic Drugs Market Value Forecast, by Application, 2018–2030

           13.4.1. Human 

               13.4.1.1. Parenchymal Neurocysticercosis

               13.4.1.2. Gastrointestinal Infections

           13.4.2. Animal

       13.5. Europe Anthelmintic Drugs Market Value Forecast, by Target Pathogen, 2018–2030

           13.5.1. Ascaris Lumbricoides (Roundworm)

           13.5.2.  Trichuris Trichiura (Whipworm 

           13.5.3. Enterobius Vermicularis (Pinworm)

           13.5.4. Ancylostoma Duodenale (Hookworm)

           13.5.5. Others

       13.6. Europe Anthelmintic Drugs Market Value Forecast, by Distribution Channel, 2018–2030

           13.6.1. Hospital Pharmacies

           13.6.2. Retail Pharmacies

           13.6.3. Online Pharmacies

           13.6.4. Veterinary Pharmacies

           13.6.5. Veterinary Hospitals & Clinics

       13.7. Europe Anthelmintic Drugs Market Value Forecast, by Country/Sub-region, 2018–2030

           13.7.1. Germany

           13.7.2. U.K.

           13.7.3. France

           13.7.4. Spain

           13.7.5. Italy

           13.7.6. Rest of Europe 

       13.8. Europe Anthelmintic Drugs Market Attractiveness Analysis

           13.8.1. By Drug Class   

           13.8.2. By Route of Administration

           13.8.3. By Application   

           13.8.4. By Target Pathogen

           13.8.5. By Distribution Channel  

           13.8.6. By Country/Sub-region

    14. Asia Pacific Anthelmintic Drugs Market Analysis and Forecast

       14.1.  Introduction

           14.1.1.  Key Findings

       14.2.  Asia Pacific Anthelmintic Drugs Market Value Forecast, by Drug Class, 2018–2030

           14.2.1. Benzimidazoles

           14.2.2. Piperazine

           14.2.3. Others

       14.3. Asia Pacific Anthelmintic Drugs Market Value Forecast, by Route of Administration, 2018–2030

           14.3.1. Oral

           14.3.2. Injectable

       14.4. Asia Pacific Anthelmintic Drugs Market Value Forecast, by Application, 2018–2030

           14.4.1. Human 

               14.4.1.1. Parenchymal Neurocysticercosis

               14.4.1.2. Gastrointestinal Infections

           14.4.2. Animal

       14.5. Asia Pacific Anthelmintic Drugs Market Value Forecast, by Target Pathogen, 2018–2030

           14.5.1. Ascaris Lumbricoides (Roundworm)

           14.5.2.  Trichuris Trichiura (Whipworm 

           14.5.3. Enterobius Vermicularis (Pinworm)

           14.5.4. Ancylostoma Duodenale (Hookworm)

           14.5.5. Others

       14.6. Asia Pacific Anthelmintic Drugs Market Value Forecast, by Distribution Channel, 2018–2030

           14.6.1. Hospital Pharmacies

           14.6.2. Retail Pharmacies

           14.6.3. Online Pharmacies

           14.6.4. Veterinary Pharmacies

           14.6.5. Veterinary Hospitals & Clinics

       14.7. Asia Pacific  Anthelmintic Drugs Market Value Forecast, by Country/Sub-region, 2018–2030

           14.7.1. China

           14.7.2. Japan

           14.7.3. India

           14.7.4. Australia & New Zealand

           14.7.5. Rest of Asia Pacific

       14.8. Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis

           14.8.1. By Drug Class   

           14.8.2. By Route of Administration

           14.8.3. By Application   

           14.8.4. By Target Pathogen

           14.8.5. By Distribution Channel  

           14.8.6. By Country/Sub-region

    15. Latin America Anthelmintic Drugs Market Analysis and Forecast

       15.1.  Introduction

           15.1.1.  Key Findings

       15.2.  Latin America Anthelmintic Drugs Market Value Forecast, by Drug Class, 2018–2030

           15.2.1. Benzimidazoles

           15.2.2. Piperazine

           15.2.3. Others

       15.3. Latin America Anthelmintic Drugs Market Value Forecast, by Route of Administration, 2018–2030

           15.3.1. Oral

           15.3.2. Injectable

       15.4. Latin America Anthelmintic Drugs Market Value Forecast, by Application, 2018–2030

           15.4.1. Human 

               15.4.1.1. Parenchymal Neurocysticercosis

               15.4.1.2. Gastrointestinal Infections

           15.4.2. Animal

       15.5. Latin America Anthelmintic Drugs Market Value Forecast, by Target Pathogen, 2018–2030

           15.5.1. Ascaris Lumbricoides (Roundworm)

           15.5.2.  Trichuris Trichiura (Whipworm 

           15.5.3. Enterobius Vermicularis (Pinworm)

           15.5.4. Ancylostoma Duodenale (Hookworm)

           15.5.5. Others

       15.6. Latin America Anthelmintic Drugs Market Value Forecast, by Distribution Channel, 2018–2030

           15.6.1. Hospital Pharmacies

           15.6.2. Retail Pharmacies

           15.6.3. Online Pharmacies

           15.6.4. Veterinary Pharmacies

           15.6.5. Veterinary Hospitals & Clinics

       15.7. Latin America Anthelmintic Drugs Market Value Forecast, by Country/Sub-region, 2018–2030

           15.7.1. Brazil

           15.7.2. Mexico

           15.7.3. Rest of Latin America

       15.8. Latin America Anthelmintic Drugs Market Attractiveness Analysis

           15.8.1. By Drug Class   

           15.8.2. By Route of Administration

           15.8.3. By Application   

           15.8.4. By Target Pathogen

           15.8.5. By Distribution Channel  

           15.8.6. By Country/Sub-region

    16. Middle East & Africa Anthelmintic Drugs Market Analysis and Forecast

       16.1.  Introduction

           16.1.1.  Key Findings

       16.2.  Middle East & Africa Anthelmintic Drugs Market Value Forecast, by Drug Class, 2018–2030

           16.2.1. Benzimidazoles

           16.2.2. Piperazine

           16.2.3. Others

       16.3. Middle East & Africa Anthelmintic Drugs Market Value Forecast, by Route of Administration, 2018–2030

           16.3.1. Oral

           16.3.2. Injectable

       16.4. Middle East & Africa Anthelmintic Drugs Market Value Forecast, by Application, 2018–2030

           16.4.1. Human 

               16.4.1.1. Parenchymal Neurocysticercosis

               16.4.1.2. Gastrointestinal Infections

           16.4.2. Animal

       16.5. Middle East & Africa Anthelmintic Drugs Market Value Forecast, by Target Pathogen, 2018–2030

           16.5.1. Ascaris Lumbricoides (Roundworm)

           16.5.2.  Trichuris Trichiura (Whipworm 

           16.5.3. Enterobius Vermicularis (Pinworm)

           16.5.4. Ancylostoma Duodenale (Hookworm)

           16.5.5. Others

       16.6. Middle East & Africa Anthelmintic Drugs Market Value Forecast, by Distribution Channel, 2018–2030

           16.6.1. Hospital Pharmacies

           16.6.2. Retail Pharmacies

           16.6.3. Online Pharmacies

           16.6.4. Veterinary Pharmacies

           16.6.5. Veterinary Hospitals & Clinics

       16.7. Middle East & Africa Anthelmintic Drugs Market Value Forecast, by Country/Sub-region, 2018–2030

           16.7.1. GCC Countries

           16.7.2. South Africa

           16.7.3. Rest of Middle East & Africa

       16.8. Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis

           16.8.1. By Drug Class   

           16.8.2. By Route of Administration

           16.8.3. By Application   

           16.8.4. By Target Pathogen

           16.8.5. By Distribution Channel  

           16.8.6. By Country/Sub-region

    17. Competitive Landscape

       17.1. Market  Player – Competition Matrix (By Tier and Size of companies)

       17.2.  Company Profiles

           17.2.1. Novartis AG 

               17.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

               17.2.1.2. Financial Overview

               17.2.1.3. Product Portfolio

               17.2.1.4. Strategic Overview

               17.2.1.5. SWOT Analysis

           17.2.2. Zoetis, Inc. 

               17.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

               17.2.2.2. Financial Overview

               17.2.2.3. Product Portfolio

               17.2.2.4. Strategic Overview

               17.2.2.5. SWOT Analysis

           17.2.3. Amneal Pharmaceuticals Inc.

               17.2.3.1.  Company Overview (HQ, Business Segments, Employee Strength)

               17.2.3.2. Financial Overview

               17.2.3.3. Product Portfolio

               17.2.3.4. Strategic Overview

               17.2.3.5. SWOT Analysis

           17.2.4. Cipla Inc. 

               17.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

               17.2.4.2. Financial Overview

               17.2.4.3. Product Portfolio

               17.2.4.4. Strategic Overview

               17.2.4.5. SWOT Analysis

           17.2.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson) 

               17.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

               17.2.5.2. Financial Overview

               17.2.5.3. Product Portfolio

               17.2.5.4. Strategic Overview

               17.2.5.5. SWOT Analysis

           17.2.6. Sun Pharmaceutical Industries Ltd

               17.2.6.1.  Company Overview (HQ, Business Segments, Employee Strength)

               17.2.6.2. Financial Overview

               17.2.6.3. Product Portfolio

               17.2.6.4. Strategic Overview

               17.2.6.5. SWOT Analysis

           17.2.7. GlaxoSmithKline plc 

               17.2.7.1.  Company Overview (HQ, Business Segments, Employee Strength)

               17.2.7.2. Financial Overview

               17.2.7.3. Product Portfolio

               17.2.7.4. Strategic Overview

               17.2.7.5. SWOT Analysis

           17.2.8.  Bayer AG

               17.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

               17.2.8.2. Financial Overview

               17.2.8.3. Product Portfolio

               17.2.8.4. Strategic Overview

               17.2.8.5. SWOT Analysis

           17.2.9. Merck & Co. Inc. (Intervet Inc.)

               17.2.9.1.  Company Overview (HQ, Business Segments, Employee Strength)

               17.2.9.2. Financial Overview

               17.2.9.3. Product Portfolio

               17.2.9.4. Strategic Overview

               17.2.9.5. SWOT Analysis

           17.2.10. Boehringer Ingelheim International GmbH 

               17.2.10.1.  Company Overview (HQ, Business Segments, Employee Strength)

               17.2.10.2. Financial Overview

               17.2.10.3. Product Portfolio

               17.2.10.4. Strategic Overview

               17.2.10.5. SWOT Analysis

    List of Tables

    Table 01: Europe Anthelmintic Drugs Market - Prevalence

    Table 02: Europe Anthelmintic Drugs Market - Prevalence

    Table 03: Global Anthelmintic Drugs Market Forecast, by Drug Class

    Table 04: Global Anthelmintic Drugs Market Forecast, by Route of Administration

    Table 05: Global Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Application, 2020–2030

    Table 06: Global Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Human, 2020–2030

    Table 07: Global Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Target Pathogen, 2018-2030

    Table 08: Global Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 09: Global Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Region, 2018-2030

    Table 10: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Country, 2018?2030

    Table 11: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018?2030

    Table 12: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018?2030

    Table 13: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Application, 2018?2030

    Table 14: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Human, 2018?2030

    Table 15: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Target Pathogen, 2018?2030

    Table 16: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018?2030

    Table 17: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018?2030

    Table 18: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018?2030

    Table 19: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Route Of Administration, 2018?2030

    Table 20: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Application, 2018?2030

    Table 21: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Human, 2018?2030

    Table 22: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Target Pathogen, 2018?2030

    Table 23: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018?2030

    Table 24: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 25: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 26: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Route Of Administration, 2018–2030

    Table 27: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Application, 2018–2030

    Table 28: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Human Application, 2018–2030

    Table 29: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Target Pathogen, 2018–2030

    Table 30: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 31: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 32: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 33: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 34: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Application, 2018–2030

    Table 35: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Human, 2018–2030

    Table 36: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Target Pathogen, 2018–2030

    Table 37: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 38: Middle East & Africa Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 39: Middle East & Africa Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 40: Middle East & Africa Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

    Table 41: Middle East & Africa Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Application, 2018–2030

    Table 42: Middle East & Africa Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Human, 2018–2030

    Table 43: Middle East & Africa Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Target Pathogen, 2018–2030

    Table 44: Middle East & Africa Anthelmintic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    List of Figures

    Figure 01: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y (%) Forecast, 2018–2030

    Figure 02: Global Anthelmintic Drugs Market Value Share, by Drug Class, 2019

    Figure 03: Global Anthelmintic Drugs Market Value Share, by Route of Administration, 2019

    Figure 05: Global Anthelmintic Drugs Market Value Share, by Target Pathogen, 2019

    Figure 04: Global Anthelmintic Drugs Market Value Share, by Application, 2019

    Figure 06: Global Anthelmintic Drugs Market Value Share, by Distribution Channel, 2019

    Figure 07: Global Anthelmintic Drugs Market Value Share, by Region, 2019

    Figure 08: North America Anthelmintic Drugs Market - Prevalence

    Figure 09: North America Anthelmintic Drugs Market - Prevalence

    Figure 10: Asia Pacific Anthelmintic Drugs Market - Prevalence

    Figure 11: Latin America Anthelmintic Drugs Market - Prevalence

    Figure 12: Middle East & Africa Anthelmintic Drugs Market - Prevalence

    Figure 13: Key Industry Developments – Anthelmintic Drugs Market

    Figure 14: Global Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 15: Global Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 16: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Benzimidazoles, 2020–2030

    Figure 17: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Piperazine, 2020–2030

    Figure 18: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2020–2030

    Figure 19: Global Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 20: Global Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 21: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Oral, 2020–2030

    Figure 22: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Injectable, 2020–2030

    Figure 23: Global Anthelmintic Drugs Market Value Share Analysis, by Application, 2019 and 2030

    Figure 24: Global Anthelmintic Drugs Market Attractiveness Analysis, by Application, 2020–2030

    Figure 25: Global Anthelmintic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Human, 2020–2030

    Figure 26: Global Anthelmintic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Animal, 2020–2030

    Figure 27: Global Anthelmintic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenchymal Neurocysticercosis, 2020–2030

    Figure 28: Global Anthelmintic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Gastrointestinal Infections, 2020–2030

    Figure 29: Global Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2019 and 2030

    Figure 30: Global Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2020–2030

    Figure 31: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Ascaris Lumbricoides (Roundworm), 2020–2030

    Figure 32: Global Anthelmintic Drugs Market value (US$ Mn) and Y-o-Y Growth (%), by Trichuris Trichiura (Whipworm), 2020–2030

    Figure 33: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Enterobius Vermicularis (Pinworm), 2020–2030

    Figure 34: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Ancylostoma Duodenale (Hookworm), 2020–2030

    Figure 35: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2020–2030

    Figure 36: Global Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 37: Global Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 38: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2020–2030

    Figure 39: Global Anthelmintic Drugs Market value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2020–2030

    Figure 40: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2020–2030

    Figure 41: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Veterinary Pharmacies, 2020–2030

    Figure 42: Global Anthelmintic Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Veterinary Hospitals and Clinics, 2020–2030

    Figure 43: Global Anthelmintic Drugs Market Value Share Analysis, by Region, 2019 and 2030

    Figure 44: Global Anthelmintic Drugs Market Attractiveness Analysis, by Region, 2020–2030

    Figure 45: North America Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018?2030

    Figure 46: North America Anthelmintic Drugs Market Value Share Analysis, by Country, 2019 and 2030

    Figure 47: North America Anthelmintic Drugs Market Attractiveness Analysis, by Country, 2020–2030

    Figure 48: North America Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 49: North America Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 50: North America Anthelmintic Drugs Market Value Share Analysis, by Route Of Administration, 2019 and 2030

    Figure 51: North America Anthelmintic Drugs Market Attractiveness Analysis, by Route Of Administration, 2020–2030

    Figure 52: North America Anthelmintic Drugs Market Value Share Analysis, by Application, 2019 and 2030

    Figure 53: North America Anthelmintic Drugs Market Attractiveness Analysis, by Application, 2020–2030

    Figure 54: North America Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2019 and 2030

    Figure 55: North America Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2020–2030

    Figure 56: North America Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 57: North America Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 58: Europe Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018?2030

    Figure 59: Europe Anthelmintic Drugs Market Value Share Analysis, by Country, 2019 and 2030

    Figure 60: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Country, 2020–2030

    Figure 61: Europe Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 62: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 63: Europe Anthelmintic Drugs Market Value Share Analysis, by Route Of Administration, 2019 and 2030

    Figure 64: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Route Of Administration, 2020–2030

    Figure 65: Europe Anthelmintic Drugs Market Value Share Analysis, by Application, 2019 and 2030

    Figure 66: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Application, 2020–2030

    Figure 67: Europe Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2019 and 2030

    Figure 68: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2020–2030

    Figure 69: Europe Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 70: Europe Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 71: Asia Pacific Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 72: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 73: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 74: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 75: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 76: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 77: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 78: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Application, 2019 and 2030

    Figure 79: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Application, 2020–2030

    Figure 80: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2019 and 2030

    Figure 81: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2020–2030

    Figure 82: Asia Pacific Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 83: Asia Pacific Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 84: Latin America Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030

    Figure 85: Latin America Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 86: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 87: Latin America Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 88: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 89: Latin America Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 90: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 91: Latin America Anthelmintic Drugs Market Value Share Analysis, by Application, 2019 and 2030

    Figure 92: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Application, 2020–2030

    Figure 93: Latin America Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2019 and 2030

    Figure 94: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2020–2030

    Figure 95: Latin America Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 96: Latin America Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 97: Middle East & Africa Anthelmintic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030

    Figure 98: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 99: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 100: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 101: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 102: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Route of Administration, 2019 and 2030

    Figure 103: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030

    Figure 104: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Application, 2019 and 2030

    Figure 105: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Application, 2020–2030

    Figure 106: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Target Pathogen, 2019 and 2030

    Figure 107: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Target Pathogen, 2020–2030

    Figure 108: Middle East & Africa Anthelmintic Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 109: Middle East & Africa Anthelmintic Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Copyright © Transparency Market Research, Inc. All Rights reserved